- Home
- GNE vs RGNX Comparison
GNE vs RGNX Comparison
Compare GNE & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNE
- RGNX
- Stock Information
- Founded
- GNE 2011
- RGNX 2008
- Country
- GNE United States
- RGNX United States
- Employees
- GNE N/A
- RGNX N/A
- Industry
- GNE Power Generation
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNE Utilities
- RGNX Health Care
- Exchange
- GNE Nasdaq
- RGNX Nasdaq
- Market Cap
- GNE 421.6M
- RGNX 372.1M
- IPO Year
- GNE N/A
- RGNX 2015
- Fundamental
- Price
- GNE $14.86
- RGNX $7.57
- Analyst Decision
- GNE
- RGNX Strong Buy
- Analyst Count
- GNE 0
- RGNX 12
- Target Price
- GNE N/A
- RGNX $35.55
- AVG Volume (30 Days)
- GNE 74.0K
- RGNX 1.8M
- Earning Date
- GNE 03-10-2025
- RGNX 02-25-2025
- Dividend Yield
- GNE 2.01%
- RGNX N/A
- EPS Growth
- GNE N/A
- RGNX N/A
- EPS
- GNE 0.12
- RGNX N/A
- Revenue
- GNE $427,221,000.00
- RGNX $84,327,000.00
- Revenue This Year
- GNE N/A
- RGNX $2.92
- Revenue Next Year
- GNE N/A
- RGNX $256.82
- P/E Ratio
- GNE $122.80
- RGNX N/A
- Revenue Growth
- GNE 5.44
- RGNX N/A
- 52 Week Low
- GNE $14.00
- RGNX $6.56
- 52 Week High
- GNE $20.33
- RGNX $28.80
- Technical
- Relative Strength Index (RSI)
- GNE 46.70
- RGNX 45.51
- Support Level
- GNE $14.54
- RGNX $6.98
- Resistance Level
- GNE $15.70
- RGNX $7.70
- Average True Range (ATR)
- GNE 0.36
- RGNX 0.54
- MACD
- GNE -0.02
- RGNX 0.04
- Stochastic Oscillator
- GNE 35.46
- RGNX 44.30
About GNE Genie Energy Ltd. Class B Stock
Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.